Y-mAbs Therapeutics (NASDAQ:YMAB) Announces Earnings Results, Misses Expectations By $0.02 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) announced its earnings results on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02), Zacks reports. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Y-mAbs Therapeutics updated its Q1 2025 guidance to EPS and its FY 2025 guidance to EPS.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $5.19 on Tuesday. Y-mAbs Therapeutics has a 12-month low of $5.13 and a 12-month high of $19.12. The company has a market capitalization of $232.45 million, a price-to-earnings ratio of -9.61 and a beta of 0.67. The firm’s fifty day moving average price is $6.58 and its 200 day moving average price is $10.72.

Analyst Upgrades and Downgrades

YMAB has been the topic of a number of research analyst reports. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target on the stock. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.